Published: Nov 19, 2021
Explore Overseas Markets to Increase Vaccine Accessibility
SHENZHEN, China, Nov. 19, 2021 /PRNewswire/ At 3 a.m.
on November 19, the first batch of more than 4 million doses of adenovirus
vector COVID-19 vaccines produced by Shenzhen Kangtai Biological Products Co.,
Ltd. will depart from Shenzhen Bao'an International Airport and will arrive in
Jakarta, capital of Indonesia, at 9 a.m. on November 19, local time. This is
the first time that the second domestic adenovirus vector COVID-19 vaccine has
been exported overseas. Including this first shipment, at least 8.4 million
doses of Kangtai adenovirus vector COVID-19 vaccines will be shipped to
Indonesia this month.
BioKangtai started to manufacture the adenovirus vector COVID-19
vaccine in February 2021, which was approved for emergency use authorization in
Indonesia on October 31. In November, BioKangtai signed a procurement contract
for the vaccine with Indonesian partner, and actively discussed the local
filling of bulk and further technology transfer of drug substance for
adenovirus vector vaccine. BioKangtai will, taking this export as a starting
point, accelerate the supply of COVID-19 vaccines to more countries, and
increase the vaccine accessibility globally, especially in developing
According to public information, the inactivated COVID-19
vaccine independently developed and produced by BioKangtai was also approved
for emergency use authorization in China in May this year, making BioKangtai
the only company in the world that possesses two types of COVID-19 vaccines
approved for emergency use authorization.
original source: https://www.prnewswire.com/news-releases/kangtai-adenovirus-vector-covid-19-vaccine-kconecavac-exported-for-the-first-time-301428966.html
SOURCE Shenzhen Kangtai Biological Products Co., Ltd.
Company Codes: Shenzhen: 300601
China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
COVID-19: A Basic Guide to Different Vaccine Types and How They Work
With global push for COVID-19 vaccines, China aims to win friends and cut deals